Last reviewed · How we verify
PHX1149T
PHX1149T is a small molecule that targets the molecular target.
PHX1149T is a small molecule that targets the molecular target. Used for unknown.
At a glance
| Generic name | PHX1149T |
|---|---|
| Also known as | dutogliptin |
| Sponsor | Phenomix |
| Drug class | small molecule |
| Target | unknown |
| Modality | Small molecule |
| Therapeutic area | unknown |
| Phase | Phase 3 |
Mechanism of action
It works by binding to the molecular target, which leads to a specific therapeutic effect.
Approved indications
- unknown
Common side effects
- unknown
Key clinical trials
- Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin (PHASE3)
- Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus (PHASE3)
- Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin (PHASE3)
- Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus (PHASE2)
- Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus (PHASE3)
- A Study to Evaluate Safety and Efficacy of PHX1149T in Subjects With Type 2 Diabetes Mellitus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PHX1149T CI brief — competitive landscape report
- PHX1149T updates RSS · CI watch RSS
- Phenomix portfolio CI